Clinical trials: Constipation Chronic Idiopathic
Chronic Idiopathic Constipation
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
To evaluate the pharmacodynamics and tolerability of a liquid formulation of lubiprostone, as compared to matching placebo, when administered orally to subjects with chronic idiopathic constipation.
- Trial name
- NCT01993875
- Testing
- Lubiprostone
- Where
- 11 sites in United States
- Volunteers
- 164 people
- Sponsor
- Mallinckrodt
Chronic Idiopathic Constipation
Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation
The objective of this study is to evaluate the clinical equivalence of the test formulation of Linaclotide compared to the marketed formulation LINZESS® in patients with Chronic Idiopathic Constipation, and to evaluate the…
- Trial name
- NCT04804267
- Testing
- Linaclotide, LINZESS®
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Idiopathic Constipation
Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC)
The was performed to assess the safety and efficacy of the vibrant capsule vs. placebo for the treatment of subjects with functional Constipation.
- Trial name
- CIC (NCT04458675)
- Testing
- Vibrant capsule
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Vibrant Ltd.
Constipation
Lubiprostone for the Treatment of Chronic Idiopathic Constipation
The purpose of this study is to evaluate the efficacy and safety of oral administration of lubiprostone 24 μg twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.
- Trial name
- NCT02651155
- Testing
- Lubiprostone
- Where
- 12 sites in Russia
- Volunteers
- 204 people
- Sponsor
- Takeda
Chronic Idiopathic Constipation
Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation
Safety and Tolerability Extension Trial for Patients with Chronic Idiopathic Constipation (CIC)
- Trial name
- NCT01895543
- Testing
- Elobixibat 10 mg
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 411 people
- Sponsor
- Ferring Pharmaceuticals
Chronic Constipation
Effect of Prucalopride in Patients With Severe Chronic Idiopathic Constipation
The purpose of this study is to determine whether prucalopride is safe and effective in patients with severe chronic constipation.
- Trial name
- NCT00576511
- Testing
- prucalopride
- Volunteers
- 53 people
- Sponsor
- Movetis
Chronic Idiopathic Constipation
Performance, Efficacy and Safety of Vibrating Capsule in Aiding Constipated Individuals
This is a study intended to evaluate the efficacy and safety of the vibrating capsule versus sham non-vibrating capsule on spontaneous bowel movement, in aiding reliving Constipated Individuals
- Trial name
- NCT02030756
- Testing
- vibrating capsule
- Where
- 18 sites in United States, Israel
- Volunteers
- 144 people
- Sponsor
- Vibrant Ltd.
Chronic Idiopathic Constipation
The Plecanatide Chronic Idiopathic Constipation (CIC) Study
This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic…
- Trial name
- NCT01429987
- Testing
- plecanatide
- Where
- 121 sites in United States
- Volunteers
- 951 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Idiopathic Constipation
Elobixibat Colonic Motor Function Study
This is a randomized trial of 36 otherwise healthy patients with chronic idiopathic constipation. The purpose of the study is to compare the effects of daily single-dose oral elobixibat and placebo for 7 days on colonic motor…
- Trial name
- NCT02392546
- Testing
- elobixibat
- Where
- United States
- Sponsor
- Ferring Pharmaceuticals
Constipation
Lubiprostone for Chronic Idiopathic Constipation Treatment
The purpose of this study is to evaluate the efficacy and safety of oral administration of 24 ug of lubiprostone twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.
- Trial name
- NCT02729909
- Testing
- Lubiprostone
- Where
- 10 sites in Mexico
- Volunteers
- 211 people
- Sponsor
- Takeda